The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

(HealthDay News) — Transcutaneous auricular vagus nerve stimulation (taVNS) reduces insomnia severity, according to a study published online Dec. 16 in JAMA Network Open.

(HealthDay News) — In a case first reported in Louisiana last Friday, a patient has now developed the first known case of bird flu so severe as to require hospitalization, according to the US Centers ...

No association seen for increased risks for dementia, cognitive impairment without dementia, accelerated cognitive decline ...

ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...

LPCN 1148 is an oral prodrug of bioidentical testosterone containing testosterone dodecanoate, an androgen receptor agonist.

(HealthDay News) — Respiratory Syncytial Virus Prefusion F (RSVpreF) vaccination is effective against RSV-related lower respiratory tract disease (LRTD) among adults aged 60 years or older, according ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

Vitamin D supplementation, with or without calcium, offers no benefit for preventing falls or fractures in community-dwelling seniors ...

(HealthDay News) — Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i), ...